HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed sentiment. While there are positive developments like productive FDA discussions and strategic partnerships, concerns arise due to limited cash reserves and lack of detailed guidance on pricing and funding. The Q&A reflects cautious optimism but lacks clarity on key issues. The strategic focus on capital efficiency and market expansion is positive, yet the absence of immediate revenue growth and the need for further funding temper expectations. Given these factors, a neutral stock price movement is anticipated over the next two weeks.
Key Financial Performance
Net Loss $5.3 million or $0.15 per basic and diluted share for the quarter ended September 30, 2025. This was consistent with the prior quarter and in line with expectations and analyst consensus. A significant portion of the net loss was related to noncash expenses such as stock-based compensation.
Net Cash Used in Operating Activities Under $3.2 million for the quarter ended September 30, 2025. This represents an 8% decrease quarter-over-quarter, building on a 23% decrease from the prior quarter. The decrease reflects the company's efforts to maintain a capital-efficient organization and judiciously time key investments into commercial readiness activities.
Cash and Cash Equivalents $1.9 million as of September 30, 2025. The company is monitoring its tight balance sheet closely and strategically funding operations to achieve near-term milestones, including FDA clearance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HeartBeam System: Developing the first-ever portable cable-free ECG that synthesizes a 12-Lead ECG. The system is designed for easy use at home, supported by on-demand cardiologists for timely care.
FDA Clearances: Received foundational FDA 510(k) clearance in December 2024 for arrhythmia assessment. Anticipating clearance for 12-Lead ECG synthesis software by year-end 2025.
Ecosystem Development: Building an ecosystem around the HeartBeam system, including automated arrhythmia assessments, integration with wearables, and AI wellness features.
Commercial Launch Strategy: Preparing for a controlled market entry in early 2026, starting with concierge and preventive cardiology practices in two U.S. regions.
Partnerships: Agreement with HeartNexus for on-demand cardiologist reviews of synthesized ECGs.
Clinical Studies: VALID-ECG pivotal study showed 93.4% diagnostic agreement with standard 12-Lead ECGs. Additional clinical trials planned for 2026 to demonstrate clinical and cost-effectiveness.
Cost Management: Net cash used in operating activities reduced by 8% quarter-over-quarter, following a 23% reduction in the prior quarter.
Strategic Pillars: Establishing HeartBeam as the first personal cable-free synthesized 12-Lead ECG system. Focus on patient experience and provider engagement to drive subscription model.
Intellectual Property: Added 3 new patents, totaling 24 worldwide. Recognized as #2 in 12-Lead ECG innovation globally.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The company is awaiting FDA 510(k) clearance for its 12-Lead ECG synthesis software for arrhythmia assessment. Any delays in obtaining this clearance could postpone the commercial launch and impact the company's strategic objectives.
Financial Constraints: The company reported a net loss of $5.3 million for the quarter and has limited cash reserves of $1.9 million as of September 30, 2025. This tight financial position could hinder operational and strategic initiatives if additional funding is not secured.
Market Entry Risks: The company plans a controlled market entry starting with a small number of concierge and preventive cardiology practices. Failure to gain traction in these initial markets could impact broader adoption and revenue generation.
Competitive Pressures: HeartBeam is entering a competitive market for at-home cardiac diagnostic devices. The success of its product depends on differentiation and adoption by both patients and healthcare providers.
Supply Chain and Commercial Readiness: The company is preparing for commercialization but has not yet fully established its sales and marketing organization. Any delays in building this infrastructure could impact the timing and success of the product launch.
Dependence on Partnerships: The company relies on partnerships, such as the agreement with HeartNexus for cardiologist services. Any issues with these partnerships could disrupt service delivery and customer satisfaction.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Clearance: HeartBeam anticipates receiving FDA 510(k) clearance for its 12-Lead ECG synthesis software for arrhythmia assessment by the end of 2025. This clearance, combined with the foundational FDA clearance received in December 2024, will enable the company to initiate its commercial launch.
Commercial Launch: The company plans to launch its HeartBeam system commercially in early 2026, starting with a controlled market entry targeting prominent concierge and preventive cardiology practices in two U.S. regions. This will be followed by broader geographic expansion.
Clinical Trials: HeartBeam expects to start enrollment in additional clinical trials in 2026 to evaluate the clinical and cost-effectiveness benefits of its system. These post-market studies will focus on adoption and reimbursement.
Commercial Readiness: HeartBeam is preparing for commercialization by hiring a Chief Commercial Officer and other key team members upon FDA clearance. Initial commercial agreements with concierge and preventive cardiology practices are anticipated.
Strategic Partnerships: The company has partnered with HeartNexus to provide on-demand board-certified cardiologist reviews of synthesized 12-Lead ECGs for arrhythmia assessment, a key component of its commercial launch strategy.
Market Strategy: HeartBeam plans to establish a small direct sales and marketing organization in the U.S., focusing initially on two geographic regions. The company is exploring distribution partnerships and subscription models to drive user retention and expansion.
Future Product Development: HeartBeam is building an ecosystem around its system, including automated arrhythmia assessments, integration with wearables, community features, and AI wellness tools. These features aim to enhance patient engagement and provide longitudinal insights for physicians.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the discussions you've had with the FDA and the factors to address ahead of clearance?
A:The CEO stated that interactions with the FDA have been productive and they anticipate FDA clearance before the end of the year. However, no further details about the characterization of the questions were provided.
Q:Are you still focused on a couple of territories initially for the commercial launch?
A:Yes, the company plans to focus on a few prominent accounts initially, which will serve as reference or pilot accounts. They will then expand to two regions to prove the sales model before scaling to a larger number of regions.
Q:How should we think about pricing for symptomatic versus asymptomatic readings?
A:The company plans a subscription offering with a one-year subscription that includes the device and access to a certain number of cardiology reads. Routine recordings will be unlimited, while symptomatic recordings will use credits and activate the reader service. Pricing details are still being worked out.
Q:How are you managing inventory levels and manufacturing capabilities for the commercial launch?
A:The company has partnered with a U.S.-based contract manufacturer using off-the-shelf components, ensuring no long lead times. Manufacturing is not a concern, and the focus is on workflow and onboarding processes.
Q:Can you provide more color on the two initial market launches and the available TAM?
A:The initial geographies are Southern California and South Florida, targeting approximately 75,000 patients in each region. The company plans a concentrated rollout with individual practices and institutions, focusing on workflow and patient experience. Significant penetration is expected by the second half of 2026 and into 2027.
Q:How do you target marketing for this out-of-pocket expense device?
A:The company targets concierge and preventive cardiology practices, working with them to reach patients. Over time, they plan to expand through referrals and potentially direct-to-consumer marketing.
Q:Are practices currently using anything similar to HeartBeam's functionality?
A:Some practices use existing one-lead ECGs, but nothing that synthesizes a 12-lead ECG with a reader service. Feedback from market research and practices has been positive, indicating incremental value in HeartBeam's offering.
Q:What are your plans for additional funding given the $2 million cash at the end of Q3?
A:The CFO mentioned optionality in funding sources and vehicles, balancing minimizing shareholder dilution with maintaining a proper balance sheet. Specific plans were not disclosed.
Q:Are there any contracts currently on the front burner?
A:The company is having discussions with potential early users, including large and prominent practices. Announcements are expected post-FDA clearance and early commercialization.
Q:What are your expectations for sales next year following commercialization?
A:The company plans to focus on user experience in the early stages, with meaningful sales growth expected in the second half of the year. They aim to accelerate growth based on demand from concierge and preventive cardiology accounts.
Q:What is the planned pathway for pursuing myocardial infarction detection after FDA clearance for arrhythmia detection?
A:The company has started discussions with the FDA and plans to pursue an expanded indication. They expect to conduct a clinical study comparing their system's performance to a 12-lead ECG in patients with ischemia or heart attacks.
Q:Will you work exclusively with HeartNexus or expand to other telecardiology firms?
A:The company is currently focused on HeartNexus, which has nationwide coverage. They are open to accounts taking on the reading function themselves but have no immediate plans to expand beyond HeartNexus.
Q:Are you considering partnering with other companies to increase production or operational capabilities?
A:Yes, the company is exploring strategic partnerships for scaling efficiently, including distribution partners and collaborations in AI algorithms, data, and co-development of pipeline technologies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on FDA questions, pricing levels, and funding plans. They also did not provide sales guidance for the next year, citing the early stages of commercialization.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
ECG Lead
ECG assessment
ECG demand
ECG synthesis
FDA application
HeartBeam Lead
HeartBeam system
HeartBeam technology
Lead ECG
Lead ECGs
ability
adoption
agreement HeartNexus
cardiologist ECG
clearance inflection
decrease
demand cardiologist
device Lead
ecosystem HeartBeam
engagement
evidence
grade
healthcare
insight patient
loss
medicine
meeting
option
parameter
patient care
patient physician
physician insight
premium
product
promise
recording HeartBeam
region
software arrhythmia
technology patient
trending
user experience
week
BEAT Transcript
HeartBeam, Inc. (BEAT) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call summary reveals strong financial discipline, a strategic focus on high-net-worth markets, and promising product development with AI collaborations. Despite some uncertainty in patient numbers and study timelines, the Q&A indicates positive sentiment towards the subscription model and revenue potential. The recent financing strengthens the company's financial position. The overall sentiment is positive, with expectations of reaching breakeven and significant revenue scaling, suggesting a stock price increase of 2-8% over the next two weeks.
HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
Unknown3-12
The company's financial performance shows a decline in revenue, which is negative, but they have strong cash reserves. The strategic plan highlights potential growth through FDA approvals and partnerships, which is positive. The Q&A reveals some uncertainties in regulatory paths and timelines, which could cause concern. Overall, the mixed signals from financials, strategic growth plans, and uncertainties result in a neutral sentiment.
HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed sentiment. While there are positive developments like productive FDA discussions and strategic partnerships, concerns arise due to limited cash reserves and lack of detailed guidance on pricing and funding. The Q&A reflects cautious optimism but lacks clarity on key issues. The strategic focus on capital efficiency and market expansion is positive, yet the absence of immediate revenue growth and the need for further funding temper expectations. Given these factors, a neutral stock price movement is anticipated over the next two weeks.
HeartBeam, Inc. (BEAT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed picture: positive aspects include a decrease in operating cash use and progress towards FDA clearance, but concerns arise from the need for additional funding and lack of detailed guidance on strategic partnerships and pricing. The Q&A section did not reveal major risks but highlighted uncertainties around commercialization timelines and partnerships. The neutral sentiment stems from balancing these positive and negative elements, with no strong catalyst for significant stock movement.
BEAT Slides
BEAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
